Preview

Системные гипертензии

Расширенный поиск

Эффективность и безопасность торасемида в лечении артериальной гипертонии в разных клинических ситуациях

Аннотация

В статье рассматриваются вопросы эффективности и безопасности применения торасемида, петлевого диуретика с дополнительным свойством антагониста минералокортикоидных рецепторов, в лечении артериальной гипертонии у разных групп пациентов.

Об авторах

Ольга Дмитриевна Остроумова
ФГБОУ ВО «МГМСУ им. А.И.Евдокимова»
Россия


Галина Федоровна Пиксина
ГБУЗ «ГКБ им. Е.О.Мухина»
Россия


Елена Анатольевна Смолярчук
ФГБОУ ВО «МГМСУ им. А.И.Евдокимова»
Россия


Елена Евгеньевна Павлеева
ФГБОУ ВО «МГМСУ им. А.И.Евдокимова»
Россия


Ольга Валентиновна Бондарец
ФГБОУ ВО «МГМСУ им. А.И.Евдокимова»
Россия


Список литературы

1. Mancia G, Fagard R, Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2013; 31: 1281-357.

2. Диагностика и лечение артериальной гипертонии: клинические рекомендации. Кардиол. вестн. 2015; 1: 3-30.

3. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваск. терапия и профилактика. 2014; 13 (4): 4-14.

4. Барышникова Г.А., Аверин Е.Е. Альдостерон при артериальной гипертензии: новые терапевтические возможности. Consilium Medicum. 2013; 15 (10): 18-23.

5. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80-91.

6. Baumgart P, Walger P, von Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in hypertension. Prog Pharmacol Clin Pharmacol 1990; 8: 169-81.

7. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63-8.

8. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittelforschung 1988; 38 (1A): 190-3.

9. Reyes A.J, Chiesa P.D, Santucci M.R. et al. Hydrochlorothiazide versus a non-diuretic dose of torasemide as oncedaily antihypertensive monopharmacotherapy in elderly patients. A randomized and double-blind study. Progress Pharmacol Clin Pharmacol 1990; 8 (1): 183-209.

10. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertensive patients with 2.5 mg torasemide/day or 50 mg triamterene/25 mg hydrochlorothiazide/day. Progress Pharmacol Clin Pharmacol 1990; 8 (Issue 1): 211-20.

11. Goodfriend T.L, Ball D.L, Oelkers W, Bahr V. Torаsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): 45-50.

12. Harada K, Izawa H, Nishizawa T et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol 2009; 53 (6): 468-73.

13. Kannel W.B. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J 1992; 13 (Suppl. D): 82-8.

14. Gonzalez A, Lopez B, Diez J. Fibrosis in hypertensive heart disease role of the angiotensin-aldosterone system. Med Clin N Am 2004; 88: 83-97.

15. Ciulla M.M, Paliotti R, Hess D.B. et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997; 10: 657-64.

16. Weber K.T, Brilla C.G, Janicki J.S. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993; 27: 341-8.

17. Остроумова О.Д., Кочетков А.И., Лопухина М.В. и др. Алгоритм выбора антигипертензивной терапии при поражении сердца как органа-мишени артериальной гипертонии. Фарматека. 2017; 9: 21-6.

18. Аверин Е.Е. Влияние торасемида на гипертрофию миокарда левого желудочка. Сердечная недостаточность. 2012; 13 (3): 158-61.

19. Lopez B, Querejeta R, Gonzales A. et al. Effects of loop diuretics on myocardial fibrosis and collage type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43 (11): 2028-35.

20. Born-Frontsberg E, Reincke M, Rump L.C. et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin. Endocrinol Metab 2009; 94 (4): 1125-30.

21. Van Sloten T.T, Stehouwer C.D. Carotid Stiffness: A Novel Cerebrovascular Disease Risk Factor. Pulse (Basel) 2016; 4 (1): 24-7.

22. Mitchell G.F. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol 2008; 105: 1652-60.

23. O’Rourke M.F, Safar M.E. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46: 200-4.

24. Tzourio C, Laurent S, Debette S. Is hypertension associated with an accelerated aging of the brain? Hypertension 2014; 63: 894-903.

25. Verdecchia P, Schillaci G, Borgioni C. et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32 (6): 983-8.

26. Benetos A, Safar M, Rudnichi A. et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30 (6): 1410-5.

27. Coca A. Effect of torasemide in monotherapy or associated to other antihypertensive drugs on pulse pressure in essential hypertension. Am J Hypertens 2002; 15 (113-114а): 231.

28. Ткачева О.Н., Рунихина Н.К., Шарашкина Н.В. Торасемид: дополнительные преимущества применения при артериальной гипертензии у женщин в постменопаузе. Системные гипертензии. 2013; 10 (2): 9-13.

29. Klag M.J, Whelton P.K, Randall B.L. et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997; 277: 1293-8.

30. Young M.J, Lam E.Y, Rickard A.J. Mineralocorticoid receprtor activator and cardiac fibrosis. Clin Sci (Lond.) 2007; 112 (9): 467-75.

31. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews ofrandomised trials. Lancet 2003; 362: 1527-35.

32. Yamato M, Sasaki T, Honda K et al. Effects of Torasemide on Left Ventricular Function and Neurohumoral Factors in Patients With Chronic Heart Failure. Circ J 2003; 67: 384-90.

33. Cosin J, Diez J. Torasemide in chronic heart failure results of the TORIC study. Eur J Heart Fail 2002; 4 (4): 507-13.

34. Murray MD, Deer MM, Ferguson J.A. et al. Open-label randomized trial of torasemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111 (7): 513-20.

35. Spannheimer A, Muller K, Falkenstein P et al. Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide? Praxis (Bern 1994) 2002; 91 (37): 1467-75.

36. Fagard R.H. Resistant hypertension. Heart 2012; 98: 254-61.

37. De la Sierra A, Segura J, Banegas J.R et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 171-4.

38. Daugherty S.L, Powers J.D, Magid D.J. et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-42.

39. Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57: 1076-80.

40. Yakovlevitch M, Black H.R. Resistant hypertension in a tertiary care clinic. Arch Int Med 1991; 151: 1786-92.

41. Zannad F. Aldosterone antagonist therapy in resistant hypertension. J Hypertens 2007; 25: 747-50.

42. Lane D.A, Shah S, Beevers D.G. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007; 25: 891-4.

43. Vaclavik J, Sedlak R, Plachy M. et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-75.

44. Chapman N, Chang CL, Dahlof B. et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008; 118: 42-8.

45. Bobrie G, Frank M, Azizi M. et al. Sequential nephron blockade vs. sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30: 1656-64.

46. Gaddam K.K, Nishizaka M.K, Pratt-Ubunama M.N. et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone and persistent intravascular volume expansion. Arch Int Med 2008; 168: 1159-64.

47. Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982; 49: 1561-3.

48. Calhoun D.A, Nishizaka M.K, Zaman M.A. et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-6.

49. Pratt-Ubunama M.N, Nishizaka M.K, Boedefeld R.L. et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131 (2): 453-9.

50. Jeunemaitre X, Chatellier G, Kreft-Jais C. et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-5.

51. Strauch B, Zelinka T, Hampf M et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17: 349-52.

52. Jessup M. Aldosterone blockade and heart failure. New Engl J Med 2003; 348: 1380-2.

53. Gaddam K.K, Nishizaka M.K, Pratt-Ubunama M.N. et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Int Med 2008; 168: 1159-64.

54. Knauf H, Mutschler E, Velazquez H, Giebisch G. Torasemide significantly reduces thiazide-induced porassium and magnesium loss despite supraadditive natriuresis. Eur J Clin Pharmacol 2009; 65 (5): 465-72.


Рецензия

Для цитирования:


Остроумова О.Д., Пиксина Г.Ф., Смолярчук Е.А., Павлеева Е.Е., Бондарец О.В. Эффективность и безопасность торасемида в лечении артериальной гипертонии в разных клинических ситуациях. Системные гипертензии. 2017;14(3):72-78.

For citation:


Ostroumova O.D., Piksina G.F., Smolyarchuk E.A., Pavleeva E.E., Bondarets O.V. The efficacy and safety of torasemid in the treatment of arterial hypertension in different clinical situations. Systemic Hypertension. 2017;14(3):72-78.

Просмотров: 2


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)